Macroaxis is not in business of monitoring Mast Therapeutics headlines and social sentiment data; there are plenty of companies out there that do it quite successfully. However, we do analyze noise-free headlines and recent hype associated with Mast Therapeutics brand which may create opportunities for some arbitrage if properly timed. With Mast Therapeutics hype-based prediction module you can estimate the value of Mast Therapeutics from the prospective of Mast Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. The module also provides analysis of price elasticity to changes in media outlook on Mast Therapeutics over a specific investment horizon. Please see also Stocks Correlation.
Mast Therapeutics is now traded for0.12. This company stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Mast Therapeutics is projected not to react to the next headline with price going to stay at about the same level and average media hype impact volatility of 0.0%. The immediate return on the next news is projected to be very small where as daily expected return is now at 0.0%. The volatility of relative hype elasticity to Mast Therapeutics is about 0.0%%. The volatility of related hype on Mast Therapeutics is about 0.0% with expected price after next announcement by competition of 0.12. About 23.0% of the company shares are owned by institutional investors. The company recorded loss per share of 0.17. Mast Therapeutics had not issued any dividends in recent years. This company had 1:25 split on April 26, 2010. Given the investment horizon of 30 days, the next projected press release will be uncertain. Please see also Stocks Correlation.